David Amsellem

Leszek Sulewski

Serge Belanger

Les Sulewski

Oren Livnat

- Knight Therapeutics Inc. announced the launch of **JORNAY PM™** (methylphenidate HCI extended-release capsules) in Canada on **October 30, 2025**, for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children aged 6-12.  **[1267565_2276971ab13c46fd96d80c0335261adb_0]** 
- JORNAY PM™ is the **first and only evening-dosed methylphenidate product** commercially available in Canada, designed to provide therapeutic benefits from waking until early evening through an innovative delayed release/extended-release technology.  **[1267565_2276971ab13c46fd96d80c0335261adb_0]** **[1267565_2276971ab13c46fd96d80c0335261adb_1]** 
- Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc. (now part of Collegium Pharmaceutical, Inc.) in **May 2024** for the exclusive rights to distribute JORNAY PM™ in Canada and Latin America.  **[1267565_2276971ab13c46fd96d80c0335261adb_0]** 
- The Canadian ADHD market totaled approximately **$1.25 billion in 2024**, with methylphenidates representing over **$500 million** and growing at more than a **14% compound annual growth rate** over the last four years.  **[1267565_2276971ab13c46fd96d80c0335261adb_0]**

COLLEGIUM PHARMACEUTICAL (COLL)